Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk

被引:36
|
作者
Kim, Jin You [1 ,2 ]
Kim, Jin Joo [1 ]
Hwangbo, Lee [1 ]
Lee, Ji Won [1 ]
Lee, Nam Kyung [1 ]
Nam, Kyung Jin [3 ]
Choo, Ki Seok [3 ]
Kang, Taewoo [4 ]
Park, Heeseung [4 ]
Son, Yohan [5 ]
Grimm, Robert [6 ]
机构
[1] Pusan Natl Univ Hosp, Med Res Inst, Dept Radiol, Busan, South Korea
[2] Pusan Natl Univ, Dept Radiol, Sch Med, 1-10 Ami Dong, Busan 602739, South Korea
[3] Pusan Natl Univ, Dept Radiol, Yangsan Hosp, Yangsan, South Korea
[4] Pusan Natl Univ Hosp, Busan Canc Ctr, Busan, South Korea
[5] Siemens Healthineers Ltd, Seoul, South Korea
[6] Siemens Healthcare GmbH, Erlangen, Germany
关键词
Diffusion magnetic resonance imaging; Breast neoplasms; Oncotype DX; Recurrence; Biomarkers; ADJUVANT SYSTEMIC THERAPY; ONCOTYPE-DX; AMERICAN-SOCIETY; EARLY-STAGE; TUMOR HETEROGENEITY; GENE-EXPRESSION; COEFFICIENT; CHEMOTHERAPY; WOMEN; SURVIVAL;
D O I
10.1007/s00330-019-06383-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives To investigate possible associations between quantitative apparent diffusion coefficient (ADC) metrics derived from whole-lesion histogram analysis and breast cancer recurrence risk in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative breast cancer who underwent the Oncotype DX assay. Methods This retrospective study was conducted on 105 women (median age, 48 years) with ER-positive, HER2-negative, node-negative breast cancer who underwent the Oncotype DX test and preoperative diffusion-weighted imaging (DWI). Histogram analysis of pixel-based ADC data of whole tumors was performed, and various ADC histogram parameters (mean, 5th, 25th, 50th, 75th, and 95th percentiles of ADCs) were extracted. The ADC difference value (defined as the difference between the 5th and 95th percentiles of ADCs) was calculated to assess intratumoral heterogeneity. Associations between quantitative ADC metrics and the recurrence risk, stratified using the Oncotype DX recurrence score (RS), were evaluated. Results Whole-lesion histogram analysis showed that the ADC difference value was different between the low-risk recurrence (RS < 18) and the non-low-risk recurrence (RS >= 18; intermediate to high risk of recurrence) groups (0.600 x 10(-3) mm(2)/s vs. 0.746 x 10(-3) mm(2)/s, p < 0.001). Multivariate regression analysis demonstrated that a lower ADC difference value (< 0.559 x 10(-3) mm(2)/s; odds ratio [OR] = 5.998; p = 0.007) and a small tumor size (<= 2 cm; OR = 3.866; p = 0.012) were associated with a low risk of recurrence after adjusting for clinicopathological factors. Conclusions The ADC difference value derived from whole-lesion histogram analysis might serve as a quantitative DWI biomarker of the recurrence risk in women with ER-positive, HER2-negative, node-negative invasive breast cancer.
引用
收藏
页码:66 / 76
页数:11
相关论文
共 50 条
  • [41] Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer
    Aline Baltres
    Zeina Al Masry
    Ryad Zemouri
    Severine Valmary-Degano
    Laurent Arnould
    Noureddine Zerhouni
    Christine Devalland
    Breast Cancer, 2020, 27 : 1007 - 1016
  • [42] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
    Matutino, A.
    Joy, A. A.
    Brezden-Masley, C.
    Chia, S.
    Verma, S.
    CURRENT ONCOLOGY, 2018, 25 : S131 - S141
  • [43] Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial
    Abdou, Yara
    Barlow, William E.
    Gralow, Julie R.
    Meric-Bernstam, Funda
    Albain, Kathy S.
    Hayes, Daniel F.
    Lin, Nancy U.
    Perez, Edith A.
    Goldstein, Lori J.
    Chia, Stephen K. L.
    Dhesy-Thind, Sukhbinder
    Rastogi, Priya
    Alba, Emilio
    Delaloge, Suzette
    Schott, Anne F.
    Shak, Steven
    Sharma, Priyanka
    Lew, Danika L.
    Miao, Jieling
    Unger, Joseph M.
    Tripathy, Debasish
    Hortobagyi, Gabriel N.
    Pusztai, Lajos
    Kalinsky, Kevin
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2025,
  • [44] Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer
    Liu, Xi-Yu
    Ma, Ding
    Xu, Xiao-En
    Jin, Xi
    Yu, Ke-Da
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    THERANOSTICS, 2018, 8 (22): : 6386 - 6399
  • [45] Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer
    Garrigos, Laia
    Camacho, Daniela
    Perez-Garcia, Jose Manuel
    Llombart-Cussac, Antonio
    Cortes, Javier
    Antonarelli, Gabriele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (10) : 949 - 958
  • [46] Response to First-line Recurrence Treatment Influences Survival in Hormone Receptor-positive, HER2-negative Breast Cancer: A Multicenter Study
    Yamamura, Jun
    Kamigaki, Shunji
    Tsujie, Masaki
    Fujita, Junya
    Osato, Hiroki
    Higashi, Chihiro
    Kanaizumi, Hirofumi
    Tanaka, Yumiko
    Hamada, Mika
    Shinzaki, Wataru
    Hashimoto, Yukihiko
    Komoike, Yoshifumi
    IN VIVO, 2019, 33 (01): : 281 - 287
  • [47] Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer
    Zheng, Hongjuan
    Ge, Chenyang
    Lin, Haiping
    Wu, Lunpo
    Wang, Qinghua
    Zhou, Shishi
    Tang, Wanfen
    Zhang, Xia
    Jin, Xiayun
    Xu, Xifeng
    Hong, Zhongwu
    Fu, Jianfei
    Du, Jinlin
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (07) : 1145 - 1153
  • [48] Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies
    Miglietta, Federica
    Dieci, Maria Vittoria
    Giarratano, Tommaso
    Torri, Valter
    Giuliano, Mario
    Zustovich, Fable
    Mion, Marta
    Tondini, Carlo Alberto
    De Rossi, Costanza
    Bria, Emilio
    Franchi, Michela
    Merlini, Laura
    Giannatiempo, Rosa
    Russo, Daniela
    Fotia, Vittoria
    Poletti, Paola
    Caremoli, Elena Rota
    Arpino, Maria Grazia
    De Salvo, Gian Luca
    Zambelli, Alberto
    Guarneri, Valentina
    EUROPEAN JOURNAL OF CANCER, 2023, 195
  • [49] Development of recurrence risk score using 95-gene classifier and its application to formalin-fixed paraffin-embedded tissues in ER-positive, HER2-negative and node-negative breast cancer
    Naoi, Yasuto
    Saito, Yuria
    Kishi, Kazuki
    Shimoda, Masafumi
    Kagara, Naofumi
    Miyake, Tomohiro
    Tanei, Tomonori
    Shimazu, Kenzo
    Kim, Seung Jin
    Noguchi, Shinzaburo
    ONCOLOGY REPORTS, 2019, 42 (06) : 2680 - 2685
  • [50] FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    Charlab, Rosane
    Chen, Wei
    Palmby, Todd
    Tilley, Amy
    Zirkelbach, Jeanne Fourie
    Yu, Jingyu
    Liu, Qi
    Zhao, Liang
    Crich, Joyce
    Chen, Xiao Hong
    Hughes, Minerva
    Bloomquist, Erik
    Tang, Shenghui
    Sridhara, Rajeshwari
    Kluetz, Paul G.
    Kim, Geoffrey
    Ibrahim, Amna
    Pazdur, Richard
    Cortazar, Patricia
    CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4760 - 4766